Literature DB >> 20146879

Expression of somatostatin receptors in human melanoma cell lines: effect of two different somatostatin analogues, octreotide and SOM230, on cell proliferation.

M Martinez-Alonso1, N Llecha, M E Mayorga, A Sorolla, X Dolcet, V Sanmartin, L Abal, J M Casanova, M Baradad, A Yeramian, R Egido, S Puig, R Vilella, X Matias-Guiu, R M Marti.   

Abstract

Somatostatin analogues (SAs) are potential anticancer agents. This study was designed to investigate the expression of somatostatin receptors (SSTRs) in melanoma cells and the effect of two SAs on cell proliferation and viability. Eighteen primary and metastatic human cutaneous melanoma cell lines were treated with octreotide and SOM230. Expression of SSTR1, SSTR2, SSTR3 and SSTR5 was assessed by real-time polymerase chain reaction. Proliferation, viability and cell death were assessed using standard assays. Inhibition was modelled by mixed-effect regression. Melanoma cells expressed one or more SSTR. Both SAs inhibited proliferation of most melanoma cell lines, but inhibition was < 50%. Neither SA affected cell viability or induced cell death. The results suggest that melanoma cell lines express SSTRs. The SAs investigated, under the conditions used in this study, did not, however, significantly inhibit melanoma growth or induce cell death. Novel SAs, combination therapy with SAs and their anti-angiogenic properties should be further investigated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20146879     DOI: 10.1177/147323000903700617

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  7 in total

1.  KE108-conjugated unimolecular micelles loaded with a novel HDAC inhibitor thailandepsin-A for targeted neuroendocrine cancer therapy.

Authors:  Guojun Chen; Renata Jaskula-Sztul; April Harrison; Ajitha Dammalapati; Wenjin Xu; Yiqiang Cheng; Herbert Chen; Shaoqin Gong
Journal:  Biomaterials       Date:  2016-04-26       Impact factor: 12.479

2.  AB3-Loaded and Tumor-Targeted Unimolecular Micelles for Medullary Thyroid Cancer Treatment.

Authors:  Renata Jaskula-Sztul; Guojun Chen; Ajitha Dammalapati; April Harrison; Weiping Tang; Shaoqin Gong; Herbert Chen
Journal:  J Mater Chem B       Date:  2016-12-02       Impact factor: 6.331

3.  Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.

Authors:  Tatyana V Masyuk; Brynn N Radtke; Angela J Stroope; Jesús M Banales; Sergio A Gradilone; Bing Huang; Anatoliy I Masyuk; Marie C Hogan; Vicente E Torres; Nicholas F Larusso
Journal:  Hepatology       Date:  2013-03-06       Impact factor: 17.425

4.  Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma.

Authors:  Reinhard Dummer; Olivier Michielin; Mirjam Chantal Nägeli; Simone M Goldinger; Federico Campigotto; Ulrike Kriemler-Krahn; Herbert Schmid; Alberto Pedroncelli; Sara Micaletto; Dirk Schadendorf
Journal:  ESMO Open       Date:  2018-07-23

5.  Co-delivery of Dacarbazine and All-Trans Retinoic Acid (ATRA) Using Lipid Nanoformulations for Synergistic Antitumor Efficacy Against Malignant Melanoma.

Authors:  Chenyang Li; Xiuping Han
Journal:  Nanoscale Res Lett       Date:  2020-05-19       Impact factor: 4.703

Review 6.  Neuroendocrine Factors in Melanoma Pathogenesis.

Authors:  Cristian Scheau; Carmen Draghici; Mihaela Adriana Ilie; Mihai Lupu; Iulia Solomon; Mircea Tampa; Simona Roxana Georgescu; Ana Caruntu; Carolina Constantin; Monica Neagu; Constantin Caruntu
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

7.  The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells.

Authors:  Su-Chen Li; Cécile Martijn; Tao Cui; Ahmed Essaghir; Raúl M Luque; Jean-Baptiste Demoulin; Justo P Castaño; Kjell Öberg; Valeria Giandomenico
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.